


Accepted Manuscript

Applying participatory action research in traumatic brain injury studies to prevent post-traumatic epilepsy

Daniel J. Correa, Churl-Su Kwon, Susan Connors, Brandy Fureman, Vicky Whittemore, Nathalie Jetté, Gary W. Mathern, Solomon L. Moshé, For the EpiBioS4Rx Public Engagement Core



PII: S0969-9961(18)30212-2
DOI: doi:[10.1016/j.nbd.2018.07.007](https://doi.org/10.1016/j.nbd.2018.07.007)
Reference: YNBDI 4217
To appear in: *Neurobiology of Disease*
Received date: 12 April 2018
Revised date: 25 June 2018
Accepted date: 4 July 2018

Please cite this article as: Daniel J. Correa, Churl-Su Kwon, Susan Connors, Brandy Fureman, Vicky Whittemore, Nathalie Jetté, Gary W. Mathern, Solomon L. Moshé, For the EpiBioS4Rx Public Engagement Core , Applying participatory action research in traumatic brain injury studies to prevent post-traumatic epilepsy. *Ynbdi* (2018), doi:[10.1016/j.nbd.2018.07.007](https://doi.org/10.1016/j.nbd.2018.07.007)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Applying Participatory Action Research in Traumatic Brain Injury Studies to Prevent Post-traumatic Epilepsy

Authors:

Daniel J. Correa, MD ^a (corresponding author: dcorrea@montefiore.org)

Churl-Su Kwon, MD, MPH ^b

Susan Connors ^c

Brandy Fureman, PhD ^d

Vicky Whittemore, PhD ^e

Nathalie Jetté, MD ^b

Gary W. Mathern, MD ^f

Solomon L. Moshé, MD ^g

For the EpiBioS4Rx Public Engagement Core

Affiliations:

- a) Saul R. Korey Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center
1410 Pelham Parkway South, K-312
Bronx, NY 10461 USA
- b) Department of Neurology, Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1137
New York, NY 10029 USA
- c) Brain Injury Association of America
1608 Spring Hill Rd # 110
Vienna, VA 22182 USA
- d) Epilepsy Foundation
8301 Professional Place East
Suite 200
Landover, MD 20785 USA
- e) National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD USA
- f) Departments of Neurosurgery and Psychiatry & BioBehavioral Sciences; David Geffen School of Medicine; University of California, Los Angeles, CA USA
- g) Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience and Department of Pediatrics, Albert Einstein College of Medicine and Montefiore Medical Center
1410 Pelham Parkway South, K-312 Bronx, NY 10461 USA

Word count:

Abstract: 202 words

Body: 4802 words (excluding figures/table)

Figure and Tables:

Figure 1: Spectrum of public/stakeholder involvement and impact in participatory action research (PAR)

Table 1: Participating organizations within the Public Engagement Core (PEC) of the Epilepsy Bioinformatics Study for Anti-Epileptogenic Therapy (EpiBioS4Rx)

Figure 2: Summary of the project phases and components for the EpiBioS4Rx Public Engagement Core (PEC) over a 5-year NIH grant period

ABSTRACT

The increased focus on stakeholder engagement in determining the aims, design, conduct of research and dissemination of results is substantially changing the biomedical research paradigm. In this era of patient-centered care, incorporating participatory action research methodology into large-scale multi-center studies is essential. The adoption of community engagement facilitates meaningful contribution to the design and implementation of clinical studies. Consequently, encouraging citizen participation and involving key organizations may guide the effective development of future clinical research protocols. Here, we discuss our experience in engaging individuals, their caregivers, as well as scientific and consumer organizations in public outreach and knowledge transfer to assist in the development of effective strategies for recruitment and retention in a future post-traumatic epilepsy prevention randomized controlled trial within the National Institute of Neurologic Disorders and Stroke Center Without Walls, Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx). The study includes a Public Engagement Core with a diverse consortium of stakeholder partners. Based on the Core's ongoing experience, it is recommended that multicenter studies integrate a participatory action research based approach to harness the benefits of a collective inquiry. The blueprint created by the EpiBioS4Rx Public Engagement Core is a resource that could be applied in other areas of biomedical research.

Keywords: Community Engagement; Participatory Action Research; Patient-Centered Outcomes; Patient Reported Outcomes; Clinical Trials; Traumatic Brain Injury; Epilepsy; Post-Traumatic Epilepsy

Abbreviations:

CWOW: Center Without Walls

EpiBioS4Rx: The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy

ESC: Epilepsy Study Consortium

IRB: Institutional Review Board

NINDS: National Institute of Neurologic Disorders and Stroke

OVC: Ohio Valley Center for Brain Injury Prevention and Rehabilitation

PAR: Participatory Action Research

PCC: Project Coordinating Committee

PCORI: Patient-Centered Outcomes Research Institute

PEC: Public Engagement Core

PCOs: Patient-Centered Outcomes

PTE: Post-Traumatic Epilepsy

REN: Rare Epilepsy Network

RCT: Randomized Controlled Trial

TBI: Traumatic Brain Injury

TBIMS: Traumatic Brain Injury Model Systems

USDHHS: United States Department of Health and Human Services

VA ECoE: Veterans Affairs Epilepsy Centers of Excellence

BACKGROUND

Introduction to Participatory Action Research (PAR)

The goal of this paper is to discuss our experience in engaging individuals, their caregivers, as well as scientific and consumer organizations in public outreach and knowledge transfer to assist in the development of effective strategies for recruitment and retention in a future post-traumatic epilepsy prevention randomized controlled trial. Participatory action research (PAR) is a qualitative research approach that emphasizes ongoing and continuous collaboration among investigators and a community targeted for research or an intervention (Reason and Bradbury, 2008). The community members participate in all stages of the research from planning, analysis to implementation as active participants. In contrast to other projects that involve community members in some aspects, PAR is designed specifically to meet the community's needs and to empower community members throughout the research process (Attree et al., 2011).

To define the aspirations and expectations of the stakeholders in a participatory process, the International Association for Public Participation (IAP2) has developed goals and core values (Participation, 2016) to ensure the relevance of the results to the participating individuals and caregivers (**Figure 1**). Guided by the knowledge-to-action cycle (Graham et al., 2006), this interactive approach starts with existing knowledge (e.g. current literature/qualitative interviews/ and focus groups), which is incorporated in the development of tools for consumers or other end-users, including educational tools. The barriers and facilitators are then evaluated, the tools are improved, implemented, and the outcomes subsequently appraised.

Figure 1: Spectrum of public/stakeholder involvement and impact in participatory action research (PAR). Content adapted from the by the International Association for Public Participation (IAP2) (Participation, 2016).



Figure 1: Spectrum of public/stakeholder involvement and impact in participatory action research (PAR)

Organizations such as the Alliance for Taxpayer Access have advocated for an open access policy to all publicly-funded research data and results for citizens (Combs, 2018). In 2013, 2015 and 2017, the United States (US) legislative branch introduced into legislative debate the Fair Access to Science and Technology Research Act (FASTR, 2018). This bill aims to accelerate scientific discovery and fuel innovation by allowing free access online for anyone to read and build upon publicly funded scientific research (FASTR, 2018). Using a PAR based approach can increase the quality and relevance of clinical and translational studies (Michener et al., 2012; Wilkins et al., 2013).

The incorporation of PAR into US healthcare research is increasingly evident following recent US legislation, including the Affordable Care Act's creation of the Patient-Centered Outcomes Research Institute (PCORI) and the 21st Century Cures Act's emphasis on putting patient perspectives first (FDA, 2016). PCORI developed a patient engagement rubric (Sheridan et al., 2017) to guide grant applicants, reviewers, and awardees on patient engagement opportunities. Also, the Milken Institute's *FasterCures* action tank developed rigorous methods to integrate the individual's perspective, needs and priorities across therapy development pipelines (FasterCures, 2017). This action tank evaluated 70 collaborative initiatives and identified 40 discrete entities providing direction for integrating perspectives of individuals and community collaboration into patient-centered care and research (Anderson and McCleary, 2015; Anderson and McCleary, 2016). Among these, the Clinical Trials Transformation Initiative developed a framework that identifies points at which clinical trial sponsors and regulators can engage patients and stakeholders in research and development (PGCT, 2017). To facilitate patient engagement in research, *FasterCures* developed a toolkit to help navigate the path to patient input highlighting the above and other resources (Anderson and McCleary, 2016; FasterCures, 2017).

Potential Barriers to PAR in Clinical Trials

There is a paucity of research regarding the value and effectiveness of different theory-informed engagement models to support actions in head equity (Davison et al., 2015; Leeuw et al., 2008). To date, clinicians and research teams design studies from their perspective of clinical equipoise between treatment arms. However, recruited individuals may have different viewpoints regarding the potential risks and benefits of treatment randomization (McGovern and McKhann, 2012). These different viewpoints may have contributed to limited recruitment in two randomized controlled trials (RCT) regarding the surgical treatment of drug-resistant epilepsy (Barbaro et al., 2018; Engel et al., 2012). To date, community engagement has not been widely used throughout the conception and implementation of a clinical trial. A 2006 Cochrane review of methods of consumer engagement in healthcare and research found that studies examining the impact of community engagement on researcher directed design were in the mental health and pain management fields (Nilsen et al., 2006). These included interventions related to consumer involvement in policy, health care implementation and development of public materials. As clinical trials differ substantially in their study design and execution, it remains unclear what are the best methods to optimize community engagement in clinical research (Nilsen et al., 2006; Richard et al., 2017).

A number of interventions to improve RCT recruitment were evaluated in several systematic reviews (Caldwell et al., 2010; Treweek et al., 2013; Watson and Torgerson, 2006). Successful recruitment interventions include telephone reminders and financial incentives. The other successful recruitment methods in this review, open-trial designs and opt-out strategies, could present logistical and ethical concerns within a preventative treatment trial (Treweek et al., 2013). A review of five United Kingdom

clinical trials across a variety of conditions (obesity, renal, mental health, falls prevention, dementia) found that in order to sustain successful recruitment of participants it is essential that all levels of the study team (e.g. site PIs, coordinators, research assistants) stay engaged in the recruitment effort (Daykin et al., 2018). A 2013 Cochrane review of RCT retention strategies, across a spectrum of conditions, focused on the participation and return of questionnaires and biomedical test kits from individuals participating in screening, treatment, or prevention interventions. This review found significantly improved retention with the addition of monetary incentives (compared with no incentive) (Bructon et al., 2013). Similarly, other reviews of retention strategies have been limited to methods of enhancing responses to telephone, postal, and/or in-person collection methods for questionnaires and longitudinal population health research (Booker et al., 2011; Edwards et al., 2009).

Public Materials as a Tool for Public Engagement

Public education materials are necessary to address the needs of individuals and their families and help in designing PAR-based RCTs. While public materials and websites may be beneficial, they can only be advantageous if individuals can read and comprehend them. The National Center for Education Statistics 2003 assessment of average reading level among Americans found an average document literacy level of 271, with 53% of adults (\geq age 16) demonstrating “intermediate” document literacy (NCES, 2003). At this level (250 to 334), adults are able to locate information in dense, complex documents and make simple inferences about the information, corresponding to a US education grade level between 7th and 9th grade (NCES, 2003). The United States Department of Health and Human Services (USDHHS) concluded that material is considered “easy to read” only if written below a 6th-grade level, 7th and 9th as “average difficulty,” and material above the 9th-grade level is regarded as “difficult”. Based on the USDHHS and recent federal guidelines on the use of plain language, public materials should be written below a 6th-grade level or when necessary at a 7th-9th grade level of reading (NIH, 2017; PLAIN, 2011).

A readability score is a calculated index that suggests a reading level or range of education needed to read and comprehend a text. One of the most common scales is the Flesch-Kincaid grade level and is bundled with word processing software such as Microsoft Word. The formula considers the average number of words per sentence as well as the average number of syllables per word (Kincaid et al., 1975). In a 2008 review of 100 consumer-oriented webpage articles from consumer organizations representing major health-related causes of death (e.g. heart disease, cancer, stroke, COPD, diabetes), the majority of the materials were written above USDHHS recommended reading levels, and 46% were above a 12th-grade level. Similar findings were reported by publications evaluating TBI and epilepsy websites (Ahmed et al., 2012; Brigo et al., 2015; Elliott et al., 2007; Elliott and Shneker, 2009).

PAR in the Traumatic Brain Injury and Epilepsy Communities

Within the TBI community, the Traumatic Brain Injury Model Systems (TBIMS) is a multicenter research project focused on assessing the delivery, demonstration, and evaluation of the ability of medical, rehabilitation and other services to meet the needs of individuals with TBI (Bushnik, 2003). The Ohio Valley Center for Brain Injury Prevention and Rehabilitation (OVC) TBIMS site pioneered PAR methods in TBI research. The OVC TBIMS has applied participatory concepts by incorporating input from an advisory panel, which included individuals living with TBI, families, and caregivers (OVC, 2017). Also at OVC, a separate PCORI-funded comparative effectiveness study of different rehabilitation approaches incorporated aspects of a PAR approach by collaborating with three stakeholder groups: a) community advisory council (individuals living with TBI), b) research team (including consumer and clinician stakeholders), c) provider advisory group (hospital administrators and researchers) on outcomes and components of the design (Bogner, 2016; OVC, 2014). Also within the TBIMS program, the Craig Hospital

site in Colorado is using a stakeholder advisory committee, qualitative interviews, online surveys, and public kits for community engagement and shared-decision making to advance patient-centered outcomes for adults living with moderate to severe TBI (CRITICAL, 2017).

Several other TBIMS centers have incorporated PAR into various pharmacologic RCTs for post-brain injury management and comparative effectiveness studies (Giacino et al., 2012; Jha et al., 2008; Morey et al., 2003). Specifically, a multicenter prospective RCT on the effectiveness of amantadine in promoting functional recovery after severe TBI required extensive stakeholder engagement due to the emotionally difficult characteristics of the study for both families and clinicians that incorporated placebos as one of the treatment arms (Giacino et al., 2012). Through multiple stakeholder forums, they explored the circumstances they would consider for participating in a placebo-controlled trial, how long families and clinicians would be comfortable with placebo treatment if an individual did not improve, concerns with enrollment and what may allay those concerns, among other themes. To our knowledge, until now, PAR methods have not been integrated into a preventative pharmacologic interventional TBI RCT or specifically to guide efforts to prevent post-traumatic epilepsy (PTE).

Within the epilepsy community, various PAR efforts have been explored. Recent examples include the establishment of the Rare Epilepsy Network (REN) (Chopra and Isom, 2014; Gattone and Lammert, 2014). The idea of a Rare Epilepsy Network originated from a discussion at the 2013 NINDS Curing the Epilepsies meeting, forging a partnership with epilepsy advocacy and professional organizations. Attending caregivers of children with rare epilepsies discussed their difficulties in deciding to create their own database or to unite across the rare epilepsy groups. This led to the PCORI funded Patient-Powered Research Network in PCORnet (Gattone and Lammert, 2014). The REN was designed to provide patients and their families an opportunity to participate in research that will improve the lives and quality of care for people with rare epilepsies. As of April 2018, the REN has enrolled 1379 participants from the US and internationally, across approximately thirty rare epilepsy syndromes (Gattone and Lammert, 2014; REN, 2018). There has been rapid progress in functional analysis and phenotypic classification of seizure types and syndromes with an acceleration of efforts to identify the underlying molecular causes and develop strategies for drug screening and prioritizing patient-centered care (Meisler et al., 2016). The data in the REN database is being analyzed in a number of ways. It is also available for researchers upon request and is publicly available for viewing on a dashboard (REN, 2018). Currently, the REN is exploring the available tools for measuring Patient-Centered Outcomes (PCOs) across epilepsy such as quality of life (for both people with epilepsy and caregivers), seizure burden, improved cognition, sleep and behavioral issues to complement existing seizure frequency measures used in studies of rare epilepsy populations.

Consumer organizations and support groups, such as the Epilepsy Foundation, are also working to define and monitor epilepsy PCOs. Using a 2016 online community survey, the Epilepsy Foundation's Epilepsy Innovation Institute collected individual and caregiver input on aspects of epilepsy that most greatly impact their lives, the frustrations they face and hopes for advancement in epilepsy research. The majority of the 1056 respondents selected unpredictability of seizures as a top issue, regardless of seizure frequency and type (Ei², 2016). With this feedback, the Epilepsy Innovation Institute (Ei²) convened a diverse group of stakeholders (patient organizations, providers, academics, professional organizations, and representatives of the pharmaceutical and device industries) in a "Seizure Gauge" workshop to assess the state of science in seizure-forecasting algorithms. This stakeholder group identified multiple non-invasive parameters to consider in addition to EEG recordings in the design of a seizure prediction device and personalized approaches to seizure forecasting (Dumanis et al., 2017).

THE EPILEPSY BIOINFORMATICS STUDY FOR ANTIEPILEPTOGENIC THERAPY (EpiBioS4Rx)

In this report, we discuss our experience in engaging individuals, their caregivers, as well as scientific and consumer organizations in public outreach and knowledge transfer toward the development of effective strategies for recruitment and retention in a future randomized controlled trial study to prevent post-traumatic epilepsy.

This is part of the Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) is a US based National Institute of Neurologic Disorders and Stroke Center Without Walls with international participation. EpiBioS4Rx includes a preclinical and clinical platform to identify candidate antiepileptogenic treatments for PTE (EpiBioS4Rx, 2016). Its objectives are to: 1) identify biomarkers of epileptogenesis in an animal model and in patients, 2) develop a standardized protocol for preclinical trials of potential antiepileptogenic therapies, and 3) create open shared resources for the entire epilepsy research community with a network of TBI centers capable of carrying out future clinical trials of potential antiepileptogenic therapies. The inclusion of public outreach and engagement is a key component for the planning of future RCTs of antiepileptogenic therapies (Engel, 2018).

The Public Engagement Core (PEC) of EpiBioS4Rx

The PEC consists of a consortium of TBI and epilepsy stakeholders (Table 1) committed to community outreach to address issues related to future RCT recruitment and retention. The PEC sought to involve a diverse sample of TBI and epilepsy stakeholders. This PTE PAR model integrates the EpiBioS4Rx research team's perspectives along with outside stakeholders including members representing the Veterans Affairs TBIMS study teams, TBI and epilepsy clinicians, consumer organizations and families/caregivers in the design of future clinical RCTs where the community has a vested interest to participate. The consumers and organizations that have dedicated their time and effort to the EpiBioS4Rx PEC are listed in Table 1.

Table 1: Participating Organizations Within the Public Engagement Core (PEC) of The Epilepsy Bioinformatics Study for Anti-Epileptogenic Therapy (EpiBioS4Rx)

EPIBIO4RX PUBLIC ENGAGEMENT CORE PARTNERS		
	Epilepsy	Traumatic Brain Injury
Service, Advocacy, Consumer, And Research Groups	Epilepsy Foundation (www.epilepsy.com)	Brain Injury Association of America (BIAA) (www.biausa.org)
	International Bureau for Epilepsy (IBE) (www.ibe.epilepsy.org)	TBI Model Systems (TBIMS) (www.tbimsc.org)
	Citizen United for Research in Epilepsy (CURE) (www.cureepilepsy.org)	
	Epilepsy Support Centre (www.epilepsysupport.ca)	
	Living Well With Epilepsy (www.livingwellwithepilepsy.com)	
	Epilepsy Awareness Organization (www.epilepsyawarenessday.org)	
	The Epilepsy Study Consortium (www.epilepsyconsortium.org)	
Veteran Organizations	Veterans Affairs (VA) Epilepsy Centers of Excellence (www.epilepsy.va.gov)	
Professional Societies	International League Against Epilepsy (ILAE) (www.ilae.org)	National Neurotrauma Society (NNS) (www.neurotrauma.org)
	American Epilepsy Society (AES) (www.aesnet.org)	International Neurotrauma Society (INS) (www.ints2014.com)
Health Organizations	World Health Organization (WHO) (www.who.int)	
	Pan American Health Organization (www.paho.org)	

Table 1: Participating organizations within the Public Engagement Core (PEC) of the Epilepsy Bioinformatics Study for Anti-Epileptogenic Therapy (EpiBioS4Rx)

The PEC consortium model is based on an integrated knowledge transfer strategy (Straus et al., 2009). This approach engages the consortium partners from study inception to dissemination.

The PEC Approach

The PEC project phases are listed below in Figure 2.

Figure 2: Summary of the project phases and components for the EpiBios4Rx Public Engagement Core (PEC) over a 5-year NIH grant period.




PHASE	EPIBIOS4RX PUBLIC ENGAGEMENT CORE
Phase 1 	Consortium development and public outreach A. Consortium and working group outreach and development B. Educate investigators and consumers about participatory action research principles C. Develop public outreach kit
Phase 2 	Community engagement and evaluation of tools A. Public surveys for direct consumer input B. Evaluate usability and the facilitators and barriers of the developed tools C. Evaluate the effectiveness of web-based public engagement strategy
Phase 3 	Evaluation of findings and trial design A. Develop template for future antiepileptogenesis trial for persons with TBI.

Figure 2: Summary of the project phases and components for the EpiBioS4Rx Public Engagement Core (PEC) over a 5-year NIH grant period.

The PEC will use a mixed-methods (qualitative and quantitative) approach to examine the determinants of public engagement, the usability of the public outreach kit (print and online materials), facilitators and barriers to RCT recruitment/retention, and future clinical RCT recruitment/retention strategy. To monitor for successful engagement, a satisfaction survey will be administered to PEC members annually, guided in part by prior satisfaction surveys (Roberts et al., 2012; Sauro et al., 2012). Findings are shared with collaborators and concerns or changes addressed to optimize team satisfaction with the engagement processes. In the questionnaire, members are invited to anonymously address the following themes: inclusiveness of the processes, respectful collaboration, the value of experiential knowledge of stakeholders, shared goals of implementation (Collier, 2011; PatientsLikeMe, 2005-2018).

Phase 1A: Consortium and Working Group Outreach and Development

A round of development was achieved with a core group of stakeholder organizations already engaged in TBI and epilepsy community health education and outreach. This core stakeholder group proposed additional members to grow the consortium through peer-to-peer outreach. PEC members were asked to participate in one of two working groups: one representing the scientific and/or researcher perspective; the other representing the perspectives of individuals, caregivers and advocacy organizations (community). The scientific working group will develop an introduction to PAR webinar and incorporate the community perspective into a recruitment and retention strategy for the future RCT. The community perspective working group is defining the important issues to individuals at risk, their families, and related community-based organizations (i.e., educational needs, concerns with research participation in RCT). Together the groups are developing an EpiBioS4Rx public outreach kit.

Phase 1B: Educate Investigators and Consumers about PAR

A review of current literature identifying PAR best practices and methodology, particularly for related studies (e.g., disease prevention studies), guided the development of a PAR webinar for PEC members. The webinar is undergoing several revisions; the final version may serve as a prologue for use in future epilepsy and TBI studies that incorporate a PAR approach.

Phase 1C: Public Outreach Kit as a Tool for Education and Engagement

To develop this kit, the PEC members were asked for information about the perceived educational needs (topics). Identified educational needs included epidemiology of TBI and PTE, epilepsy comorbidities, meaningful use of biomarkers, concerns regarding participation in RCTs and experiential stories from individuals and families that have participated in prior TBI and epilepsy research.

An exploratory TBI focus group (consisting of individuals living with TBI) was run by one of the PEC member consumer organizations to determine if the suggested educational needs were adequate or if there were additional gaps. One of the gaps identified included confusion with terms related to epilepsy, PTE, biomarkers, and RCTs. Several PEC members with experience in public education materials for persons with TBI and/or epilepsy also raised concerns about the target age/grade levels for reading comprehension (readability of text). This feedback informed the development of a draft of educational materials, consisting of definitions of key terms related to TBI, epilepsy, PTE, and EpiBioS4Rx.

To develop these education materials, the Flesch-Kincaid reading ease score and grade level tests were used to assess the readability of a convenience sample of public materials on TBI, epilepsy, and PTE. A majority of the publicly available content in this convenience sample scored at a Flesch-Kincaid 12th-grade level or higher. The exceptions were the epilepsy materials from the “Living well with Epilepsy” and the Epilepsy Foundation web pages, which scored with an average of 7th and 9th-grade levels respectively (EpilepsyFoundation, 2017; LivingWellWithEpilepsy, 2017). For the Epilepsy Foundation, this represents an improvement in readability after a 2009 health literacy assessment found that only 25% of its webpage content was at or below the 9th-grade level, averaging at the 11th-grade level (Elliott and Shneker, 2009). Based on the Department of Health and Human Services recommendations and the complexity of the concepts related to TBI and PTE, it was determined that the PEC public materials should target a 9th grade English reading level. After modifying the materials, the TBI focus group reevaluated the first round of public materials, and their feedback will be incorporated into the continued development of the kit. The public materials kit will include items such as a TBI and PTE factsheet (English and Spanish), content related to RCT participation, ICU care, and secondary outcomes associated with TBI, including the association with epilepsy. Once the website and toolkit are developed, the utilization will be examined over time. The prototype public outreach kit (including the associated

website), with the existing and the newly developed materials, will then undergo further usability testing to ensure the materials and website meets the needs of the intended users. Focus groups will also be run with a sample of 5-8 potential end users, representing a cross-section of experiences from people with TBI, PTE, family members, and consumer groups.

The final toolkit will be provided to members for coordinated dissemination. The partner organizations' online portals will be monitored for which materials are disseminated (e.g. via the internet or social networks). The success of the distribution will be assessed by correlating increases in web traffic to the EpiBioS4Rx public engagement website with the distribution time points. The tracking will help identify which materials and messages are most relevant to various subpopulations (e.g., those with PTE, those at risk of PTE, civilian, military, caregivers, providers, outside investigators), and which formats are most likely to be voluntarily distributed online by organizations. Increasing the understanding of how message content, formats, the timing of public engagement (i.e., what prompts action and when) will add to the body of knowledge on PAR implementation and knowledge translation methods in both epilepsy and TBI.

Phase 2: Community Engagement and Evaluation of Tools

The second phase is focused on the development and testing of strategies for involving both consumers and consumer groups in the design of studies, the determination of usability of the developed tools, and identification of potential facilitators and barriers to future RCT recruitment and retention. Following the evaluation of each tool, a Knowledge Exchange Forum will be hosted with the stakeholders to share the findings (Holroyd-Leduc et al., 2017; Sauro et al., 2016). This will allow for meaningful feedback from stakeholders and ensure the objectives and tools developed are focused on issues that resonate with them.

In addition to focus groups, the PEC will seek input from outside investigators and larger consumer groups through the development of qualitative and quantitative, population-based, cross-sectional surveys of potential consumers. Questions for consumers (stratified by multiple variables including respondent demographics such as age, sex, race, socioeconomic status, education) will examine topics such as the right time to discuss PTE risk, right person with whom to discuss risk, factors that are mandatory knowledge for participation, aspects that would facilitate participation, previous history of any study participation and optimal methods of communication.

Using the public website as a web-based public engagement platform, PEC members, consumers, and consumer groups will be asked to participate by providing feedback to inform the design characteristics of the 'mock' therapeutic trial of antiepileptogenesis after TBI. Quantitative analysis will include measures on the stakeholder's perspective of specific RCT design, intervention type, and monitoring methods characteristics as facilitators or barriers to future study recruitment and retention. These qualitative and quantitative findings will help optimize and enhance the public engagement tools and future trial design.

As needed, multiple rounds of an iterative Delphi-like approach (Bennett et al., 2015; Eubank et al., 2016; Jette et al., 2012; McMillan et al., 2016) will be used to reach consensus regarding final components of the trial design, recruitment and retention strategies. The data will be analyzed by determining the number and quality of changes proposed by the consumer/consumer groups that are successfully incorporated in the RCT design as well as the number of Delphi-like rounds required.

Phase 3: Evaluation of Findings and Trial Design

The sustained engagement of the PEC collaborators will be assessed by compiling results of the evaluation plans associated with each step of the study and metrics such as website visitation rates and satisfaction scores for produced outside materials. The final evaluative variables of the PAR approach will be determined in collaboration with the PEC and the working groups but may include indicators such as length of participation or service on working groups and number of attendees at events.

Using the outcome measures defined by the PEC and EpiBioS4Rx research team, a template recruitment/retention strategy will be developed by the PEC. This strategy, along with the findings from each of the EpiBioS4Rx projects will be incorporated into a blueprint for the future clinical RCT of TBI antiepileptogenesis design. Once the future RCT is completed; the data will be reassessed to determine the impact of the incorporated suggestions on recruitment and retention.

DISCUSSION AND RECOMMENDATIONS:

The unique design of the EpiBioS4Rx study with multi-center collaboration of concurrent studies in basic science, clinical biomarkers, and drug screening provides the community with a unique engagement effort to benefit patients with TBI who may develop PTE. To achieve this goal, stakeholders were selected based on knowledge, clinical expertise or research area through peer-to-peer outreach. At this stage, the consortium represents a multi-level group of stakeholders that is broad and representative of the fields of TBI and epilepsy. Moving forward, representation will be expanded by recruiting other stakeholders through multiple organizations and seeking a broad range of educational levels, sex, race, ethnicity and socioeconomic status.

Using this PAR approach, EpiBioS4Rx and the PEC are innovating clinical trial development in several ways through:

1. The development of research strategy and goals with the active participation of consumer groups and researchers.
2. The inclusion of specific populations particularly those more likely to experience head trauma, such as veterans. The exploration of sex differences and the best way to engage underserved populations.
3. Early public engagement from study inception to identify best strategies for recruitment, retention and knowledge transfer for a future PTE prevention trial.
4. Participation of international organizations for greater universal applicability and incorporation of feedback from other countries that have large populations with different attitudes regarding epilepsy and TBI.

The purpose of the PEC's contribution to EpiBioS4Rx is a rigorous study with public members as active partners with a vested stake in a future RCT. The EpiBioS4Rx clinical study is recruiting individuals who have suffered a moderate or severe TBI who do not have a diagnosis of epilepsy, although deemed at risk of developing PTE.

The PEC is working to remove possible barriers through education and support. For example, the ICU setting poses unique changes in the design and implementation of an RCT. Acutely, many individuals with moderate to severe TBIs may be mechanically ventilated and/or unresponsive (e.g., comatose).

When the individual is unresponsive, there may be limited understanding and even with adequate understanding, the barrage of emotions in an ICU can make the commitment to a long-term preventative RCT seem abstract. In addition, individuals with TBI may require extended monitoring due to the biphasic nature of the acute TBI and subsequent PTE with often a prolonged interval of months to years between TBI (first phase/stimulus) and the clinical presentation of epilepsy (second phase/response). Furthermore, during the prolonged rehabilitation phase after TBI, individuals may depend substantially on their family for decision-making and logistical and emotional support. Identifying and addressing the needs and concerns of individuals and their families early on is essential to the enrollment process, sustained participation, and implementation of the RCT.

A significant concern is that, in a prevention study such as the proposed future PTE prevention trial, the physical and psychological consequences of a seizure to individuals/caregivers are theoretical at the time of the enrollment. The PEC began addressing this problem by creating educational materials emphasizing two specific needs of the TBI community: the importance of an appropriate reading level and the need for translated and culturally sensitive content. In particular, Spanish-language materials were identified as important given the growing United States Spanish-speaking community. Within the future RCT, this may be the largest potential “English as a second language” group. To address this need, the PEC added a Spanish language subgroup of three clinicians (representing a variety of Spanish dialects) and a Spanish-speaking veteran living with TBI. This subgroup will assist in translating the produced materials and ensuring they are culturally sensitive.

Given the growing complexities of healthcare and medical research paradigms, we recommend that investigators consider community engagement, i.e., PAR, in all stages of clinical study design. PAR is unique because it integrates theory, basic science, clinical perspectives and community input to improve clinical studies, fosters a feedback loop, and ensure relevance of research aims and outcomes to the community of interest. PAR engagement may be enhanced by social media, the development of public materials (including websites) and a strong marketing strategy. These approaches can be resource intensive; therefore, incorporating PAR in clinical research must be planned carefully. Research teams should consider budgeting for additional resources to optimize their public outreach strategy and the success of any PAR guided clinical studies. Employing PAR methodology in the planning and implementation of future clinical trials has the potential to enhance study participation, retention, implementation and ultimately outcomes for those living with neurological conditions such as epilepsy and TBI. Prospective research is needed to identify best methods and evaluate the efficacy of integrating PAR into an RCT.

Acknowledgments:

This work is supported by NIH grants 1U54NS100064 EpiBioS4Rx, Center Without Walls and Einstein-Montefiore CTSA Grant Number UL1TR001073.

EpiBioS4Rx Public Engagement Core

We thank the many contributors to the development and ongoing optimization of the EpiBioS4Rx Public Engagement Core collaboration (listed alphabetically):

Denise Bartley; Edward H. Bertram; Allen W. Brown; Jorge Burneo; Dennis Dlugos; R. Andrew David; Sunita Dergalust; Tracy Dixon-Salazar; Phillip M. Gattone; Alison Heffer; Jessica Kennan Smith; Robert Kotloski; Lara Lubbers; Brad Levy; Candy Levy; Victor Medina; Juan Ochoa; Karen Parko; Mary Jo Pugh; Edwin Trevathan; David J. Thurman; Mary Secco; Richard Segal; Joanna Segal; Jorge Vidaurre.

Author acknowledgments:

Daniel José Correa, MD drafted the manuscript, table 1 and figures, review editing and final approval. He is supported by the NIH 1U54NS100064 grant and by NIH/National Center for Advancing Translational Science (NCATS) Einstein-Montefiore CTSA Grant Number UL1TR001073.

Churl-Su Kwon, MD, MPH contributed to the manuscript draft and edited table and figure. He is supported by the NIH 1U54NS100064 grant

Susan Connors contributed to the stakeholder input, manuscript review, editing and final approval.

Brandy Fureman, PhD contributed to the stakeholder input, manuscript review, editing and final approval.

Vicky Holets Whittemore, PhD contributed to the stakeholder input, review and final approval of the manuscript.

Nathalie Jetté, MD contributed to the manuscript editing, interpretation, editing and final approval. She holds research support paid to her academic center from Alberta Health, the Canadian Institutes of Health Research and the National Institute of Health 1U54NS100064.

Gary W. Mathern contributed to the stakeholder input, manuscript review, editing and final approval. He is the Davies/Crandall endowed chair for epilepsy research at UCLA and NIG grant RO1 NS 38992

Solomon L. Moshé contributed to the manuscript editing, interpretation, and final approval. He is the Charles Frost Chair in Neurosurgery and Neurology and funded by grants from NIH NS43209 and 1U54NS100064, Department of Defense EPI70020, CURE Infantile Spasms Initiative, US Department of Defense (W81XWH-13-1-0180), the Heffer Family and the Segal Family Foundations and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families.

Disclosures:

Daniel J. Correa, MD receives tuition funding and support from the US Army Post 9/11 G.I. Bill (Serviceman's Readjustment Act).

Churl-Su Kwon, MD MPH has no disclosures.

Susan Connors is the president and chief executive officer of the Brain Injury Association of America, and a federally registered lobbyist. Ms. Connors has served in advisory capacities and on expert panels for several federal agencies, universities, and nonprofit organizations and has authored numerous publications, position statements, and articles.

Brandy Fureman, PhD is the Vice President of Research and New Therapies for the Epilepsy Foundation, which is supported by revenue from philanthropy, corporate sponsorships, and federal grants.

Vicky Holets Whittemore, PhD is the National Institute of Neurologic Disorders and Stroke (NINDS) in the Channels, Synapses and Circuits Cluster at the National Institutes of Health, Bethesda, Maryland. She has 23 years of prior experience working for nonprofit organizations including the Tuberous Sclerosis Alliance, Genetic Alliance, Citizens United for Research in Epilepsy (CURE), and the National Coalition for Health Professional Education in Genetics (NCHPEG).

Nathalie Jetté, MD receives an annual compensation for her work as an Associate Editor of Epilepsia.

Gary W. Mathern serves on the editorial board of Neurology

Solomon L. Moshé MD is serving as Associate Editor of Neurobiology of Disease and is on the editorial board of Brain and Development, Pediatric Neurology and Physiological Research. He receives from Elsevier an annual compensation for his work as Associate Editor in Neurobiology of Disease and royalties from 2 books he co-edited. He has received consultant's fees from Eisai, UCB and Mallinckrodt.

ACCEPTED MANUSCRIPT

References

- Ahmed, O. H., et al., 2012. Concussion information online: evaluation of information quality, content and readability of concussion-related websites. *Br J Sports Med.* 46, 675-83. <https://doi.org/10.1136/bjsm.2010.081620>.
- Anderson, M., McCleary, K. K., 2015. From passengers to co-pilots: Patient roles expand. *Sci Transl Med.* 7, 291fs25. <https://doi.org/10.1126/scitranslmed.aac6023>.
- Anderson, M., McCleary, K. K., 2016. On the path to a science of patient input. *Sci Transl Med.* 8, 336ps11. <https://doi.org/10.1126/scitranslmed.aaf6730>.
- Attree, P., et al., 2011. The experience of community engagement for individuals: a rapid review of evidence. *Health Soc Care Community.* 19, 250-60. <https://doi.org/10.1111/j.1365-2524.2010.00976.x>.
- Barbaro, N. M., et al., 2018. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled ROSE trial. *Epilepsia.* <https://doi.org/10.1111/epi.14045>.
- Bennett, D. A., et al., 2015. Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. *Eur J Epidemiol.* 30, 569-76. <https://doi.org/10.1007/s10654-015-0034-5>.
- 2016, Comparative Effectiveness of Rehabilitation Interventions for Traumatic Brain Injury - ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT02646176>, (accessed March 12th, 2018).
- Booker, C. L., et al., 2011. A systematic review of the effect of retention methods in population-based cohort studies. *BMC Public Health.* 11, 249. <https://doi.org/10.1186/1471-2458-11-249>.
- Brigo, F., et al., 2015. Clearly written, easily comprehended? The readability of websites providing information on epilepsy. *Epilepsy Behav.* 44, 35-9. <https://doi.org/10.1016/j.yebeh.2014.12.029>.
- Brueton, V. C., et al., 2013. Strategies to improve retention in randomised trials. *Cochrane Database Syst Rev.* MR000032. <https://doi.org/10.1002/14651858.MR000032.pub2>.
- Bushnik, T., 2003. Introduction: the Traumatic Brain Injury Model Systems of Care. *Arch Phys Med Rehabil.* 84, 151-2. <https://doi.org/10.1053/apmr.2003.50123>.
- Caldwell, P. H., et al., 2010. Strategies for increasing recruitment to randomised controlled trials: systematic review. *PLoS Med.* 7, e1000368. <https://doi.org/10.1371/journal.pmed.1000368>.
- Chopra, R., Isom, L. L., 2014. Untangling the dravet syndrome seizure network: the changing face of a rare genetic epilepsy. *Epilepsy Curr.* 14, 86-9. <https://doi.org/10.5698/1535-7597-14.2.86>.
- Collier, R., 2011. Federal government unveils patient-oriented research strategy. *CMAJ.* 183, E993-4. <https://doi.org/10.1503/cmaj.109-3978>.
- @EurekAlertAAAS, 2018, Alliance for Taxpayer Access asks NIH 'Who really owns publicly-funded medical research?', http://www.eurekalert.org/pub_releases/2005-01/wc-aft011305.php, (accessed 2018).
- University of Colorado Anschutz Medical Campus - School of Medicine Physical Medicine and Rehabilitation, 2017, Coalition for Recovery and Innovation in Traumatic Brain Injury Care Across the Lifespan (CRITICAL), <http://www.ucdenver.edu/academics/colleges/medicalschool/departments/pmr/Research/Pages/CRITICAL.aspx>, (accessed January 15th, 2018).
- Davison, C. M., et al., 2015. Critical examination of knowledge to action models and implications for promoting health equity. *Int J Equity Health.* 14, 49. <https://doi.org/10.1186/s12939-015-0178-7>.
- Daykin, A., et al., 2018. 'Recruitment, recruitment, recruitment' - the need for more focus on retention: a qualitative study of five trials. *Trials.* 19, 76. <https://doi.org/10.1186/s13063-018-2467-0>.

- Dumanis, S. B., et al., 2017. Seizure Forecasting from Idea to Reality. Outcomes of the My Seizure Gauge Epilepsy Innovation Institute Workshop. *eNeuro*. 4. <https://doi.org/10.1523/ENEURO.0349-17.2017>.
- Edwards, P. J., et al., 2009. Methods to increase response to postal and electronic questionnaires. *Cochrane Database Syst Rev*. MR000008. <https://doi.org/10.1002/14651858.MR000008.pub4>.
- Epilepsy Innovation Institute (Ei2) Community Survey, Ei2, Epilepsy Foundation, <https://www.epilepsy.com/sites/core/files/atoms/files/community-survey-report-2016%20V2.pdf>, 2016.
- Elliott, J. O., et al., 2007. A health literacy assessment of the National Epilepsy Foundation Web site. *Epilepsy Behav*. 11, 525-32. <https://doi.org/10.1016/j.yebeh.2007.08.021>.
- Elliott, J. O., Shneker, B. F., 2009. A health literacy assessment of the epilepsy.com website. *Seizure*. 18, 434-9. <https://doi.org/10.1016/j.seizure.2009.04.003>.
- Engel, J., Jr., 2018. Epileptogenesis, traumatic brain injury, and biomarkers. *Neurobiol Dis*. <https://doi.org/10.1016/j.nbd.2018.04.002>.
- Engel, J., Jr., et al., 2012. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. *JAMA*. 307, 922-30. <https://doi.org/10.1001/jama.2012.220>.
- Administrative Core EpiBioS4Rx, Laboratory of Neuroimaging, Keck School of Medicine, University of Southern California, 2016, Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx), <http://epibios.loni.usc.edu/>, (accessed Dec 10th, 2016).
- Epilepsy Foundation of America®, 2017, Epilepsy.com [Homepage], <https://www.epilepsy.com/>, (accessed May 10th, 2017).
- Eubank, B. H., et al., 2016. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. *BMC Med Res Methodol*. 16, 56. <https://doi.org/10.1186/s12874-016-0165-8>.
- F. Cures, Patients Count, Milken Institute, <http://www.fastercures.org/programs/patients-count/science-of-patient-input-resources/>, 2017.
- SPARC, 2018, Fair Access to Science & Technology Research Act (FASTR) FAQ, <https://sparcopen.org/our-work/fastr/faq/>, (accessed 2018).
- Federal Drug Administration (FDA), 2016, 21st Century Cures Act, <https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/21stCenturyCuresAct/default.htm>, (accessed January 15th, 2018).
- Gattone, P., Lammert, W., 2014. The Epilepsy Foundation leads in the Rare Epilepsy Network PCORI Award. *Epilepsy Behav*. 39, 65. <https://doi.org/10.1016/j.yebeh.2014.08.008>.
- Giacino, J. T., et al., 2012. Placebo-controlled trial of amantadine for severe traumatic brain injury. *N Engl J Med*. 366, 819-26. <https://doi.org/10.1056/NEJMoa1102609>.
- Graham, I. D., et al., 2006. Lost in knowledge translation: time for a map? *J Contin Educ Health Prof*. 26, 13-24. <https://doi.org/10.1002/chp.47>.
- Holroyd-Leduc, J. M., et al., 2017. Stakeholder Meeting: Integrated Knowledge Translation Approach to Address the Caregiver Support Gap. *Can J Aging*. 36, 108-119. <https://doi.org/10.1017/S0714980816000660>.
- Jette, N., et al., 2012. Development of an online tool to determine appropriateness for an epilepsy surgery evaluation. *Neurology*. 79, 1084-93. <https://doi.org/10.1212/WNL.0b013e3182698c4c>.
- Jha, A., et al., 2008. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. *J Head Trauma Rehabil*. 23, 52-63. <https://doi.org/10.1097/01.HTR.0000308721.77911.ea>.
- Kincaid, J., et al., Derivation of new readability formulas (Automated Readability Index, Fog Count and Flesch Reading Ease Formula) for Navy-enlisted personnel. In: C. o. N. T. Training, (Ed.). Chief of Naval Technical Training: Naval Air Station, U.S. Naval Air Station; Memphis, TN, 1975.

- Leeuw, E. d., et al., 2008. Theoretical reflections on the nexus between research, policy and practice. *Critical Public Health*. 18, 5-20. <https://doi.org/10.1080/09581590801949924>.
- Living Well With Epilepsy, LLC, 2017, Living Well With Epilepsy [Homepage], <https://livingwellwithepilepsy.com/>, (accessed May 7th, 2017).
- McGovern, R. A., McKhann, G. M., 2nd, 2012. The ERSET trial of early surgery for mesial temporal lobe epilepsy: results and frustrations. *Neurosurgery*. 70, N23-4. <https://doi.org/10.1227/01.neu.0000414949.94342.cf>.
- McMillan, S. S., et al., 2016. How to use the nominal group and Delphi techniques. *Int J Clin Pharm*. 38, 655-62. <https://doi.org/10.1007/s11096-016-0257-x>.
- Meisler, M. H., et al., 2016. SCN8A encephalopathy: Research progress and prospects. *Epilepsia*. 57, 1027-35. <https://doi.org/10.1111/epi.13422>.
- Michener, L., et al., 2012. Aligning the goals of community-engaged research: why and how academic health centers can successfully engage with communities to improve health. *Acad Med*. 87, 285-91. <https://doi.org/10.1097/ACM.0b013e3182441680>.
- Morey, C. E., et al., 2003. The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. *Brain Inj*. 17, 809-15. <https://doi.org/10.1080/0269905031000088586>.
- A First Look at the Literacy of America's Adults in the 21st Century (supplemental data retrieved July 6, 2006). Table 507.10. Literacy skills of adults, by type of literacy, proficiency levels, and selected characteristics: 1992 and 2003, National Center for Education Statistics (NCES), U.S. Department of Education, 2003.
- National Institutes of Health (NIH), U.S. Department of Health & Human Services, 2017, Plain Language at NIH, <https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/clear-communication/plain-language>, (accessed June 8th, 2017).
- Nilsen, E. S., et al., 2006. Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material. *Cochrane Database Syst Rev*. CD004563. <https://doi.org/10.1002/14651858.CD004563.pub2>.
- Ohio State University, Wexner Medical center, 2014, Ohio Valley Center (OVC) is approved for almost \$1 million research funding award by the Patient-Centered Outcomes Research Institute, <http://ohiovalley.org/article.cfm?ID=8402>, (accessed January 15th, 2018).
- The Ohio State's Wexner Medical Center, Grant #H133A120086 awarded by the U.S. Department of Education, National Institute on Disability Rehabilitation Research (NIDRR), 2017, Ohio Regional Model System at the Ohio Valley Center (OVC) for Brain Injury Prevention and Rehabilitation., <http://ohiovalley.org/modelsystems/ohioregionalms/>, (accessed March 12th, 2018).
- International Association of Public Participation, Australasia, 2016, International Association of Public Participation (IAP2) spectrume of public participation tool kit, <https://www.iap2.org/?page=pillars>, (accessed September 9th, 2016).
- PatientsLikeMeInc., 2005-2018, PatientsLikeMe.com, <http://www.patientslikeme.com/join/poem>, (accessed September 16, 2017).
- Patient Groups & Clinical Trials (PGCT) Project, Clinical Trials Transformation Initiative, 2017, ENGAGE EARLY. ENGAGE OFTEN. Realizing the Value of Effective Patient Group Engagement, <https://www.ctti-clinicaltrials.org/projects/patient-groups-clinical-trials>, (accessed December 10th, 2017).
- Federal Plain Language Guidelines, Plain Language Action and Information Network (PLAIN), <https://www.plainlanguage.gov/guidelines/>, 2011.
- Reason, P., Bradbury, H., 2008. The Sage handbook of action research : participative inquiry and practice. SAGE Publications, London ; Thousand Oaks, Calif.
- 2018, Rare Epilepsy Network (REN) - home page, <https://ren.rti.org/>, (accessed

- Richard, L., et al., 2017. Advancing engagement methods for trials: the CORE study relational model of engagement for a stepped wedge cluster randomised controlled trial of experience-based co-design for people living with severe mental illnesses. *Trials*. 18, 169. <https://doi.org/10.1186/s13063-017-1878-7>.
- Roberts, J. I., et al., 2012. Using a standardized assessment tool to measure patient experience on a seizure monitoring unit compared to a general neurology unit. *Epilepsy Behav.* 24, 54-8. <https://doi.org/10.1016/j.yebeh.2012.03.002>.
- Sauro, K. M., et al., 2016. Knowledge translation of an online tool to determine candidacy for epilepsy surgery evaluation. *Neurol Clin Pract.* 6, 304-314. <https://doi.org/10.1212/CPJ.0000000000000250>.
- Sauro, K. M., et al., 2012. Experience and satisfaction of staff working in a seizure monitoring unit. *Can J Neurosci Nurs.* 34, 33-8.
- Sheridan, S., et al., 2017. The PCORI Engagement Rubric: Promising Practices for Partnering in Research. *Ann Fam Med.* 15, 165-170. <https://doi.org/10.1370/afm.2042>.
- Straus, S. E., et al., 2009. Defining knowledge translation. *CMAJ.* 181, 165-8. <https://doi.org/10.1503/cmaj.081229>.
- Treweek, S., et al., 2013. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. *BMJ Open.* 3. <https://doi.org/10.1136/bmjopen-2012-002360>.
- Watson, J. M., Torgerson, D. J., 2006. Increasing recruitment to randomised trials: a review of randomised controlled trials. *BMC Med Res Methodol.* 6, 34. <https://doi.org/10.1186/1471-2288-6-34>.
- Wilkins, C. H., et al., 2013. Community representatives' involvement in Clinical and Translational Science Awardee activities. *Clin Transl Sci.* 6, 292-6. <https://doi.org/10.1111/cts.12072>.